abs257.txt	purpose		her2	+	breast	cancer	(bc)	is	an	aggressive	subtype	with	high	rates	ofbrain	metastases	(bcbm)		two-thirds	of	her2	+	bcbm	demonstrate	activation	of	thepi3k/mtor	pathway	driving	resistance	to	anti-her2	therapy		this	phase	ii	studyevaluated	everolimus	(e)		a	brain-permeable	mtor	inhibitor		trastuzumab	(t)		andvinorelbine	(v)	in	patients	with	her2	+	bcbm	patients	and	methods		eligible	patients	had	progressive	her2	+	bcbm		the	primaryendpoint	was	intracranial	response	rate	(rr)		secondary	objectives	were	cnsclinical	benefit	rate	(cbr)		extracranial	rr		time	to	progression	(ttp)		overallsurvival	(os)		and	targeted	sequencing	of	tumors	from	enrolled	patients		atwo-stage	design	distinguished	intracranial	rr	of	5%	versus	20%	results		32	patients	were	evaluable	for	toxicity		26	for	efficacy		intracranialrr	was	4%	(1	pr)		cns	cbr	at	6	mos	was	27%		at	3	mos	65%		median	intracranial	ttpwas	3	9	mos	(95%	ci	2	2-5)		os	was	12	2	mos	(95%	ci	0	6-20	2)		grade	3-4toxicities	included	neutropenia	(41%)		anemia	(16%)		and	stomatitis	(16%)	mutations	in	tp53	and	pik3ca	were	common	in	bcbm		mutations	in	the	pi3k/mtorpathway	were	not	associated	with	response		erbb2	amplification	was	higher	in	bcbmcompared	to	primary	bc		erbb2	amplification	in	the	primary	bc	trended	towardworse	os	conclusion		while	intracranial	rr	to	etv	was	low	in	her2	+	bcbm	patients	one-third	achieved	cns	cbr		ttp/os	was	similar	to	historical	control		no	newtoxicity	signals	were	observed		further	analysis	of	the	genomic	underpinnings	ofbcbm	to	identify	tractable	prognostic	and/or	predictive	biomarkers	is	warranted	clinical	trial		(nct01305941)	
